Halofuginone Hydrobromide

• CAT Number: R051332
• CAS Number: 64924-67-0
• Molecular Formula: C16H18Br2ClN3O3
• Molecular Weight: 495.59
• Purity: ≥95%
• Synonyms: rel-7-Bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4(3H)-quinazolinone Hydrobromide; trans-(+/-)-7-Bromo-6-chloro-3-[3-(3-hydroxy-2-?piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone Monohydrobromide; RU 19110; Stenorol
• Target: TGF-beta/Smad
• Storage: 3 years -20℃ powder
• IUPAC Name: 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide
• InChI: InChI=1S/C16H17BrClN3O3.BrH/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14;/h5-6,8,14-15,19,23H,1-4,7H2;1H/t14-,15+;/m0./s1
• InChIKey: SJUWEPZBTXEUMU-LDXVYITESA-N
• SMILES: C1C[C@H]([C@@H](NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O.Br

Halofuginone Hydrobromide（Cat No.:R051332）is a derivative of the natural quinazolinone alkaloid halofuginone, known for its diverse pharmacological properties. It inhibits collagen type I synthesis and the TGF-β/Smad signaling pathway, making it a valuable compound in fibrosis research. Additionally, it exhibits anti-inflammatory, antiparasitic, and antitumor activities by modulating pathways involved in cellular proliferation and immune response. Halofuginone Hydrobromide is widely studied for its potential therapeutic applications in conditions such as fibrosis, autoimmune diseases, and certain cancers. Its broad bioactivity highlights its significance in biomedical research and drug development.